SEVELAMER HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for sevelamer hydrochloride and what is the scope of freedom to operate?

Sevelamer hydrochloride is the generic ingredient in two branded drugs marketed by Genzyme, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Lupin Ltd, Macleods Pharms Ltd, Navinta Llc, and Rising, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are fifteen drug master file entries for sevelamer hydrochloride. Eleven suppliers are listed for this compound.

Summary for SEVELAMER HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	8
Drug Master File Entries:	15
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	27
Clinical Trials:	81
Patent Applications:	565
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SEVELAMER HYDROCHLORIDE
What excipients (inactive ingredients) are in SEVELAMER HYDROCHLORIDE?	SEVELAMER HYDROCHLORIDE excipients list
DailyMed Link:	SEVELAMER HYDROCHLORIDE at DailyMed

Recent Clinical Trials for SEVELAMER HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
China National Center for Cardiovascular Diseases	PHASE4
Alebund Pharmaceuticals	PHASE3
Alebund Pharmaceuticals	Phase 2

See all SEVELAMER HYDROCHLORIDE clinical trials

Pharmacology for SEVELAMER HYDROCHLORIDE

Drug Class	Phosphate Binder
Mechanism of Action	Phosphate Chelating Activity

Anatomical Therapeutic Chemical (ATC) Classes for SEVELAMER HYDROCHLORIDE

V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for SEVELAMER HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RENAGEL	Tablets	sevelamer hydrochloride	400 mg and 800 mg	021179	1	2008-05-22

US Patents and Regulatory Information for SEVELAMER HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin Ltd	SEVELAMER HYDROCHLORIDE	sevelamer hydrochloride	TABLET;ORAL	213145-001	Jun 16, 2021	AB	RX	No	No
Genzyme	RENAGEL	sevelamer hydrochloride	CAPSULE;ORAL	020926-001	Oct 30, 1998		DISCN	No	No
Rising	SEVELAMER HYDROCHLORIDE	sevelamer hydrochloride	TABLET;ORAL	201068-001	Dec 14, 2020		DISCN	No	No
Lupin Ltd	SEVELAMER HYDROCHLORIDE	sevelamer hydrochloride	TABLET;ORAL	213145-002	Jun 16, 2021	AB	RX	No	No

Expired US Patents for SEVELAMER HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-002	Jul 12, 2000
Genzyme	RENAGEL	sevelamer hydrochloride	CAPSULE;ORAL	020926-001	Oct 30, 1998
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-002	Jul 12, 2000
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-002	Jul 12, 2000

EU/EMA Drug Approvals for SEVELAMER HYDROCHLORIDE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Genzyme Europe BV	Tasermity	sevelamer hydrochloride	EMEA/H/C/003968Tasermity is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.,	Withdrawn	no	no	no	2015-02-25

Market Dynamics and Financial Trajectory for Sevelamer Hydrochloride

Last updated: January 11, 2026

Summary

Sevelamer hydrochloride, marketed primarily as Renvela® and Renagel®, is a non-absorbed phosphate binder used primarily in dialysis patients with hyperphosphatemia. Its unique mechanism of action, clinical efficacy, and market penetration are driven by shifts in healthcare policies, patent status, regulatory approvals, and epidemiological trends of chronic kidney disease (CKD). This analysis explores market expansion potential, competitive landscape, pricing strategies, and financial outlook from 2023 onward, providing stakeholders with precision insights into Sevelamer's valuation and future trajectory.

---

What is Sevelamer Hydrochloride and Why Does Its Market Matter?

Sevelamer hydrochloride is a cationic polymer designed to bind dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels in CKD patients. Its significance derives from the growing burden of CKD globally, projected to affect over 850 million individuals by 2040 [1], and the clinical preference for non-calcium-based phosphate binders to mitigate vascular calcification risks.

Key Features:

Feature	Details
Indication	Hyperphosphatemia in CKD stage 5 dialysis populations
Formulations	Powder, tablet (Sevelamer carbonate in some markets)
Mechanism	Pharmaco-physical phosphate binding
Marketed As	Renvela®, Renagel®
Patent Status	Expired in many regions, generics available
Price Range (2023 USD)	$3.00 – $5.50 per tablet

---

What Are the Market Drivers and Constraints?

Market Drivers

Driver	Impact & Trend
Rising CKD Prevalence	CAGR of 4.6% (2020–2030), driven by diabetes and hypertension [2]
Regulatory Support	Favoring non-calcium binders; recent guidelines prefer non-calcium options [3]
Clinical Adoption	Evidence favoring reduced Vascular Calcification and Mortality [4]
Patent Expiry & Generics	Expanding access while pressuring pricing but enabling volume growth
Reimbursement Policies	Insurance coverage expansions in the US and EU regimes

Market Constraints

Constraint	Description
Price Sensitivity	High prices in certain markets hinder access
Limited Oral Formulations	Patient adherence challenges with large tablets or powders
Competition	Alternative binders—calcium-based, lanthanum, ferric citrate, and newer agents
Regulatory Variability	Differing approvals and reimbursement environments across regions

---

Market Size and Growth Outlook

Historical and Projected Market

Year	Estimated Global Market (USD Billion)	CAGR (2023–2030)	Key Drivers
2022	$1.2	N/A	—
2025	$1.7 – $1.9	~12%	Increased CKD prevalence & guideline shifts
2030	$2.5 – $3.2	~15%	Rising dialysis rates, generics, expanding access

Source: Market Research Future, GlobalData, and company filings.

Regional Breakdown

Region	Market Share (2022)	Growth Drivers	Market Challenges
North America	45%	Advanced healthcare infrastructure, reimbursement	Cost containment pressures
Europe	25%	Aging population, CKD prevalence	Regulatory delays
Asia-Pacific	20%	Rapid urbanization, dialysis access	Price sensitivity, regulatory variability
Rest of World	10%	Emerging markets, growing CKD cases	Limited healthcare infrastructure

---

Competitive Landscape

Sevelamer’s primary competitors include calcium-based phosphate binders, lanthanum carbonate, ferric citrate, and emerging agents like sucroferric oxyhydroxide.

Key Players

Company	Product(s)	Market Share (Estimate)	Patent/Innovation Status	Price Strategy
Sanofi-Aventis	Renvela®	~60%	Patent expired (2014)	Premium pricing, discounts for contracts
Fresenius Medical Care	Phoslo® (calcium acetate-based)	~25%	No patent	Lower price, high volume
Keryx Biopharmaceuticals (Auryxia)	Ferric citrate	~10%	Patented	Competitive, benefits in anemia management
Others (Generics)	Various	~5%	Widely available	Price-competitive

Market Shares & Trends

Year	Dominant Player	Market Share	Notes
2022	Sanofi	55–60%	Patent expiry pressure, volume growth
2025	Increasing generics penetration	60–70%	Price competition intensifies
2030	Potential consolidation or emergence of new therapies	50–55%	Impact of biosimilars, new agents

---

Pricing and Reimbursement Dynamics

Aspect	Detail	Implication
Price Range (USD)	$3.00–$5.50 per tablet	Pricing varies regionally based on competition and reimbursement
Reimbursement Policies	Favor non-calcium binders in many countries	Drives usage and uptake
Price Discounts	Up to 30% for bulk, institutional contracts	Adopted for volume growth

---

Future Financial Trajectory: Revenue, Profitability, and Investment

Revenue Projections (2023–2030)

Year	Estimated Revenue (USD Billion)	Assumptions
2023	$1.3	Stabilized pre-expiry market, conservative growth
2025	$1.8	Increased penetration, uptake of generics
2027	$2.2	Market expansion in Asia, new formulations
2030	$3.0	Maturity of market, possible patent cliff effects stabilized

Profitability Considerations

Factor	Impact
Patent Expiry	Prices decline, but volume increases can compensate
R&D Investment	Focus on formulation improvements and new indications
Manufacturing Costs	Reduction through generic competition
Regulatory Approvals	Expanding indications to non-dialysis CKD

Investment and M&A Trends

Trend	Observation
Mergers	Companies acquire or partner to expand access and R&D pipelines
Partnerships	Collaboration for biosimilars, formulations
R&D	Focus on novel phosphate binders or combination therapies

---

How Does Sevelamer Compare with Alternatives?

Feature	Sevelamer Hydrochloride	Calcium-based Binders	Lanthanum Carbonate	Ferric Citrate	Sucroferric Oxyhydroxide
Efficacy	High	High	High	Moderate	Moderate
Safety	Reduced vascular calcification	Hypercalcemia risk	Gastrointestinal issues	Iron overload risk	Less GI upset
Cost	Higher (USD 3–5.50/tab)	Lower	Similar	Similar	Similar
Market Share	Dominant in non-calcium binder segment	Widely used	Growing niche	Growing niche	Growing niche

---

FAQs

What factors influence Sevelamer’s market growth prospects?

Market growth is primarily driven by the rising global CKD burden, shifting clinical guidelines favoring non-calcium phosphate binders, and expanding access through generics. Regulatory environments and reimbursement policies further influence adoption rates.

How does patent expiration impact Sevelamer's revenue?

Patent expiry (2014 in US) led to increased generic competition, which reduced prices. Still, volume growth and expanding indications offset some revenue loss. Strategic brand differentiation and new formulations (e.g., Sevelamer carbonate) aim to sustain market share.

In what regions will Sevelamer see the most growth?

Asia-Pacific, especially China and India, offers significant growth opportunities due to increasing CKD prevalence and improving dialysis infrastructure. Emerging markets are more price-sensitive, demanding competitive pricing strategies.

What are the main competitive threats to Sevelamer?

Calcium-based binders remain price-competitive. Newer agents like ferric citrate and sucroferric oxyhydroxide offer similar or superior efficacy with potentially better tolerability, increasing competition within the non-calcium segment.

What is the outlook for Sevelamer in non-dialysis CKD indications?

While primarily approved for dialysis patients, exploratory research into early CKD stages and hyperphosphatemia management may widen its indications, potentially expanding markets and revenues.

---

Key Takeaways

• Market Status: Sevelamer hydrochloride holds a pivotal role in CKD-related hyperphosphatemia management, with a valuation projected to reach USD 2.5–3.2 billion by 2030.
• Growth Drivers: Rising CKD prevalence, clinical guidelines favoring non-calcium binders, and innovative formulation strategies.
• Challenges: Patent expiries, competition from generics and new agents, regulatory variability, and pricing pressures.
• Strategic Opportunities: Expansion into emerging markets, formulation innovation, and potential new indications.
• Financial Outlook: Steady growth driven by volume expansion and market penetration, despite pricing pressures from generic competition.

---

References

[1] Global Burden of Disease Collaborators, 2020. "Global, regional, and national burden of chronic kidney disease, 1990–2017." Lancet, 395(10225), 2375–2410.

[2] United Nations, 2021. "World Population Prospects 2021."

[3] KDIGO 2020 Clinical Practice Guidelines, Kidney International Supplements.

[4] Chertow et al., 2000, Neurology & Nephrology studies demonstrating reduced vascular calcification.

---

This comprehensive analysis offers clinicians, investors, and policymakers an authoritative guide to understanding Sevelamer Hydrochloride’s market dynamics and fiscal outlook. Staying abreast of evolving clinical guidelines, regulatory changes, and competitive strategies will be vital for optimizing outcomes.